Cargando…
FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy
Hepatotoxicity is a common side effect for patients treated with gefitinib, but the related pathogenesis is unclear and lacks effective predictor and management strategies. A multi-omics approach integrating pharmacometabolomics, pharmacokinetics and pharmacogenomics was employed in non-small cell l...
Autores principales: | Guan, Shaoxing, Chen, Xi, Chen, Youhao, Wan, Guohui, Su, Qibiao, Liang, Heng, Yang, Yunpeng, Fang, Wenfeng, Huang, Yan, Zhao, Hongyun, Zhuang, Wei, Liu, Shu, Wang, Fei, Feng, Wei, Zhang, Xiaoxu, Huang, Min, Wang, Xueding, Zhang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513443/ https://www.ncbi.nlm.nih.gov/pubmed/36176901 http://dx.doi.org/10.1016/j.apsb.2022.02.006 |
Ejemplares similares
-
Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer
por: Guan, Shaoxing, et al.
Publicado: (2020) -
The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
por: Xin, Shuang, et al.
Publicado: (2015) -
Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020) -
Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019) -
ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)